A multi-site, double-blind, placebo-controlled trial of memantine vs. placebo in children with autism targeting memory and motor planning
ID Number 11-0410Principal Investigator(s)
Department(s) or Division(s)
This study examines the role of memantine (brand name: Namenda) on improving memory, language, and motor abilities in children with Autism Spectrum Disorders (ASDs). Funded by Autism Speaks’ Clinical Trial Network (CTN), this study is designed to further investigate promising preliminary data on the potential role of memantine in improving these important skill areas in children with ASD. Participants will be randomized to receive 24 weeks (6 months) of treatment with memantine or placebo (sugar pill). Participants who did not show improvements and were randomized to placebo are eligible to receive the drug under the clinical care of a study psychiatrist for a 12-week period.
Recruiting Patients: Yes